Lipocine Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019. Lipocine is a clinical-stage pharmaceutical company focused on oral drug-delivery products. It has no product-sale revenue; its lead candidate is TLANDO, an oral testosterone replacement therapy. The financial statements are unaudited.
Financial performance and liquidity
- Revenue: $0, versus $428,031 in Q1 2018, when revenue consisted of Spriaso royalty payments.
- Operating expenses: $3.13 million, up 2% from $3.07 million. R&D rose to $1.95 million from $1.38 million, mainly due to TLANDO’s ABPM study; G&A declined to $1.18 million from $1.69 million.
- Loss: Operating loss was $3.13 million versus $2.64 million; net loss was $3.22 million versus $2.72 million. Basic and diluted loss per share were $0.14, compared with $0.13.
- Cash flow: Operating cash use was $3.00 million, down from $3.75 million. Investing activities used $2.08 million, primarily reflecting net purchases of marketable securities. Financing provided $5.23 million, principally from ATM stock sales, offset by $833,000 of debt repayments. Cash and cash equivalents increased $145,000 during the quarter.
- Liquidity: Cash and cash equivalents were $8.22 million and marketable securities were $9.30 million; together, unrestricted liquid resources were $17.52 million, versus $15.25 million at December 31, 2018. A further $5.0 million was restricted as loan collateral. Current assets were $22.95 million and current liabilities $4.28 million.
- Debt: Carrying value totaled approximately $9.49 million ($3.33 million current; $6.16 million non-current) under a $10 million Silicon Valley Bank facility. The stated interest rate was 6.5% at quarter-end; the loan matures December 1, 2021 and includes a $650,000 final payment charge.
- Other: Accumulated deficit was $141.3 million. No product gross margin is reported because the company had no revenue in the quarter.
Material changes and developments
- Net loss increased by approximately $505,000 year over year as the company had no license revenue and spent more on R&D. The increase in R&D was concentrated in TLANDO external study costs; lower personnel and professional costs reduced G&A.
- The company sold 2.84 million shares through its ATM program in Q1 at a weighted-average price of $2.20, generating $6.1 million net proceeds. Outstanding common shares were 24.57 million at March 31; 21.57 million were reported outstanding as of May 6.
- Clarus’s JATENZO received FDA approval on March 27, 2019, adding an approved oral competitor. Lipocine filed a patent-infringement action against Clarus on April 3; Clarus asserted counterclaims.
Outlook, risks and contingencies
- Management expected to resubmit the TLANDO NDA in May 2019 and stated that existing capital resources were expected to fund projected operations through at least March 31, 2020. This outlook depends on assumptions; management said additional capital would ultimately be needed. Funding availability, timing of FDA review, clinical requirements, and spending levels could change the runway.
- Management expected approximately $2.5 million in additional TLANDO R&D costs to complete the ABPM study work and resubmit the NDA, subject to timing and cost uncertainties. The company planned to focus 2019 efforts primarily on TLANDO and LPCN 1144.
- TLANDO had received two FDA Complete Response Letters. The latest identified issues involving blood-pressure effects, possible ex vivo conversion in blood samples, Cmax data, and stopping criteria. The ABPM study reported mean changes of 3.82 mm Hg in 24-hour systolic and 1.20 mm Hg in diastolic blood pressure. The definitive phlebotomy study found no statistically significant conversion under specified processing conditions. FDA acceptance or approval of a resubmission was not assured, and additional studies, delay, labeling restrictions, or further capital needs remained possible.
- LPCN 1144’s encouraging liver-fat findings came from a small, single-arm proof-of-concept study; the company planned to dose the first participant in a Phase 2 study in Q3 2019. Management cautioned that early results may not predict later trial outcomes.
- The company reported a shareholder derivative suit alleging fiduciary-duty breaches and unjust enrichment tied to statements about TLANDO’s NDA. It intended to defend the case and recorded no liability because a loss was not considered probable or estimable. Clarus appealed the PTAB decision canceling claims in its patent; the appeal and Lipocine’s infringement lawsuit remain material legal uncertainties.
- Other notable risks include continuing operating losses, dependence on external financing, potential dilution, competition, and loan covenants. The $5.0 million cash restriction lapses only if TLANDO is FDA-approved. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the TLANDO NDA was resubmitted, accepted for review, and what FDA action or additional requirements followed.
- TLANDO’s blood-pressure results and the implications for labeling, REMS, or further cardiovascular studies.
- Cash burn, unrestricted liquidity, ATM issuance and dilution, and progress toward additional financing as clinical spending evolves.
- Progress and results of the planned LPCN 1144 Phase 2 study, and whether the patent and shareholder litigation changes materially.